Imcyse SA
Imcyse to present late-breaking abstract of its ImotopeTM-based antigen-specific immunotherapy for autoimmune diseases at ASIT 2020
DGAP-News: Imcyse SA
/ Key word(s): Conference
Imcyse to present late-breaking abstract of its
Liège, Belgium, February 24, 2020 – Imcyse a clinical-stage biopharmaceutical company pioneering the development of a new class of active, specific immunotherapies for the treatment of severe chronic autoimmune diseases, today announced that the Company will present a late-breaking abstract on its ImotopeTM-based antigen specific immunotherapies for autoimmune diseases at the 3rd Antigen-Specific Immune Tolerance summit 2020 (ASIT), taking place in Boston, MA, February 25 – 27. ASIT is considered the thought-leading platform dedicated to overcoming key challenges currently impeding drug development for tolerance inducing therapeutics. The oral presentation by Prof. Antoon van Oosterhout, PhD, CSO and Vice President R&D of Imcyse, is entitled Bench-to-bedside: ImotopeTM-based antigen-specific immunotherapy for autoimmune diseases. The presentation will take place on Wednesday, February 26, 2020 from 3:30 pm – 4:00 pm at The Colonnade Hotel, Boston, MA. Imcyse’s ImotopesTM represent a next generation potentially curative approach to severe chronic diseases for which there is no satisfactory therapeutic alternative. ImotopesTM induce cytolytic T cells that specifically eliminate antigen-presenting cells and autoantigen specific lymphocytes without affecting other functions of the immune system. Recently, Imcyse completed a Phase Ib study of insulin-based ImotopeTM IMCY-0098, results showed an excellent safety profile and promising clinical trends. The company is also developing an ImotopeTM pipeline for the treatment of other autoimmune diseases. Details of the oral presentation: Prof. Antoon van Oosterhout, CSO and Vice President R&D of Imcyse, and Luc Vander Elst, R&D Director of Imcyse, will be available for one-on-one meetings with interested parties over the course of the conference. ABOUT IMCYSE CONTACT
24.02.2020 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |